Literature DB >> 28459238

Efficacy and advantages of modified Traditional Chinese Medicinezzm321990treatments based on "kidney reinforcing" for chronic aplastic anemia:zzm321990a randomized controlled clinical trial.

Dijiong Wu, Yiping Shen, Baodong Ye, Bingmu Fang, Shengyun Lin, Zhilu Chen, Huifang Jiang, Changwei Feng, Lüyuan He, Yanting Gao, Yonglin Liu, Yonghua Liu, Jiajia Zhu, Liqiang Wu, Keding Shao, Shao Keding, Yuhong Zhou.   

Abstract

OBJECTIVE: To compare the efficacy of modified treatments based on "kidney reinforcing" in the management of chronic aplastic anemia (CAA), and explore their advantages and specialties.
METHODS: One hundred and eleven patients with CAA were randomly divided into three groups: kidney reinforcing alone (KA), "kidney reinforcing and Qi tonifying" (KQ), and "kidney reinforcing and blood circulation invigorating" (KC). Normal and positive control groups were also formed. All patients were treated for 6 months (two courses). Hemograms, Traditional Chinese Medicine (TCM) syndrome scores, and therapeutic effects were assessed, and changes in T-lymphocyte subsets, regulatory T cells and cytokines were detected.
RESULTS: The KQ and KC groups had lower TCM syndrome scores than the positive control group after 6 months (P < 0.05). The KQ group had a higher overall efficacy than the positive control group after 3 months (P < 0.05), while platelet counts increased in the KC group after 6 months (P < 0.05). CD3+ T-lymphocyte ratios decreased only in the KQ group, while CD3 + CD4 + CD8 − Tlymphocytes increased only in the KC group after 6 months (P < 0.05). Levels of interferon-γ, tumor necrosis factor tor-α, interleukin (IL)-2 and IL-6 decreased and levels of IL-4 and IL-10 increased in all treated groups after 6 months. Levels of IL-6 in the KQ and KC groups were lower than those in the positive control group (P < 0.05).
CONCLUSION: Treatments based on kidney reinforcing have a rebalancing effect on cytotoxic and T helper cells, and regulate expression of interferon- γ, IL-2, IL-6 and IL-4. KQ may be more effective in treating CAA, and KC may have an advantage in platelet recovery.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28459238     DOI: 10.1016/s0254-6272(16)30059-0

Source DB:  PubMed          Journal:  J Tradit Chin Med        ISSN: 0255-2922            Impact factor:   0.848


  8 in total

1.  Effects of Jianpi Bushen Therapy for Treatment of CKD Anemia: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Liang Li; Chengyin Li; Yu Zhou; Qi Xu; Zilin Wang; Xiaoyun Zhu; Yuanming Ba
Journal:  Front Pharmacol       Date:  2020-09-15       Impact factor: 5.810

2.  A composite mouse model of aplastic anemia complicated with iron overload.

Authors:  Dijiong Wu; Xiaowen Wen; Wenbin Liu; Linlong Xu; Baodong Ye; Yuhong Zhou
Journal:  Exp Ther Med       Date:  2017-11-17       Impact factor: 2.447

3.  Metabolomics-Based Clinical Efficacy of Compound Shenlu Granule, a Chinese Patent Medicine, in the Supportive Management of Aplastic Anemia Patients: A Randomized Controlled Pilot Trial.

Authors:  Zhou Feng; Xiaoying Hu; Weiying Qu; Xiaoqin Zhu; Jiaying Lu; Zhongdi Huang; Lin Zhao; Pei Chen
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-30       Impact factor: 2.629

4.  Differentiation of Yin, Yang and Stasis Syndromes in Severe Aplastic Anemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation and Their Correlation with Iron Metabolism, cAMP/cGMP, 17-OH-CS and Thyroxine.

Authors:  Huijin Hu; Tao Chen; Wenbin Liu; Yiping Shen; Qiushuang Li; Yuhong Zhou; Baodong Ye; Dijiong Wu
Journal:  J Blood Med       Date:  2021-11-13

5.  Effects of Sodium Chlorophyllin Copper on APO-1 Expression in Bone Marrow Mesenchymal Stem Cells of Rats with Aplastic Anaemia.

Authors:  Xin Jin; Guanhai Dai; Liyang Xuan; Meng Zhang; Huifang Jiang; Yang Sui
Journal:  J Immunol Res       Date:  2022-04-06       Impact factor: 4.818

6.  Bushen Jianpi Quyu Formula Alleviates Myelosuppression of an Immune-Mediated Aplastic Anemia Mouse Model via Inhibiting Expression of the PI3K/AKT/NF-κB Signaling Pathway.

Authors:  Hangchao Li; Lina Ji; Yingying Shen; Danqing Fu; Dijiong Wu; Baodong Ye
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-14       Impact factor: 2.650

7.  Medication Regularity of Traditional Chinese Medicine in the Treatment of Aplastic Anemia Based on Data Mining.

Authors:  Nanxi Dong; Xujie Zhang; Dijiong Wu; Zhiping Hu; Wenbin Liu; Shu Deng; Baodong Ye
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-25       Impact factor: 2.650

8.  Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.

Authors:  Dijiong Wu; Xiaowen Wen; Wenbin Liu; Huijin Hu; Baodong Ye; Yuhong Zhou
Journal:  Drug Des Devel Ther       Date:  2018-05-03       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.